M&A Deal Summary

Xeris Acquires Strongbridge Biopharma

On May 24, 2021, Xeris acquired life science company Strongbridge Biopharma for 267M USD

Acquisition Highlights
  • This is Xeris’ 1st transaction in the Life Science sector.
  • This is Xeris’ largest (disclosed) transaction.
  • This is Xeris’ 1st transaction in the United States.
  • This is Xeris’ 1st transaction in Pennsylvania.

M&A Deal Summary

Date 2021-05-24
Target Strongbridge Biopharma
Sector Life Science
Buyer(s) Xeris
Deal Type Add-on Acquisition
Deal Value 267M USD

Target

Strongbridge Biopharma

Trevose, Pennsylvania, United States
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. Strongbridge Biopharma was founded in 1996 and is based in Trevose, Pennsylvania.

Search 199,713 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Xeris

Chicago, Illinois, United States

Category Company
Founded 2005
Sector Life Science
Employees377
Revenue 164M USD (2023)
DESCRIPTION

Xeris is a pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world. With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke in the U.S. Its proprietary XeriSol and XeriJect formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system. Xeris was founded in 2005 and is based in Chicago, Illinois.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1